Johnson & Johnson Innovative Medicine

What Johnson & Johnson Innovative Medicine does

Johnson & Johnson Innovative Medicine operates as a pharmaceutical division of Johnson & Johnson (NYSE: JNJ), delivered through the Janssen R&D and commercial franchise and headquartered in Raritan, New Jersey. The organization develops prescription therapeutics for serious and difficult-to-treat medical conditions, with cited focus areas spanning oncology, retina, and cell therapy, as indicated by named VP-level leaders in Global Retina, Cell Therapy Discovery, and a Senior Director of REMS & Risk Management. Its lead disclosed asset is pasritamig (KLK2-CD3), a first-in-class bispecific T-cell engager designed to redirect T cells against kallikrein 2-expressing prostate cancer cells for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

The unit advances its pipeline through early-stage clinical development. On March 19, 2026, it entered a clinical supply agreement with Korean biotech GI Innovation to evaluate GI Innovation's immuno-oncology agent GI-102 in combination with pasritamig in a Phase 1b trial. The study is being conducted across the United States and Korea, with Asan Medical Center and Severance Hospital participating alongside Columbia University, which serves as the global coordinating site. Operating geographies confirmed in the source data cover North America (USA) and East Asia (Korea).

The business model is anchored in the parent company's pharmaceutical commercialization infrastructure: clinical assets developed within this division are intended to be commercialized through Johnson & Johnson's established global sales, regulatory, and distribution channels rather than through an independent go-to-market. The input provides no divisional pricing, revenue, contract, or capital-raise data; commercial economics are inherited from JNJ's broader Innovative Medicine segment and are not separately disclosed at the divisional level in the supplied sources.

Name

Johnson & Johnson Innovative Medicine

Legal name

Johnson & Johnson Innovative Medicine

Website

https://janssen.com

Company type

Public

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Johnson & Johnson Innovative Medicine is a pharmaceutical division of Johnson & Johnson, developing therapeutics through the Janssen franchise. It advances bispecific T-cell engagers, with lead asset pasritamig for metastatic castration-resistant prostate cancer, and runs clinical trials across the US and Korea.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), CAR-T & TCR-T Therapies (HLAAABAC), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Pharmaceutical research
• Oncology therapeutics
• Bispecific antibodies
• Immuno-oncology treatments
• Clinical drug development

Headquarters

HQ city

Raritan

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Core offering

Johnson & Johnson Innovative Medicine develops and researches pharmaceutical treatments, with a focus on oncology therapeutics including bispecific T-cell engagers and immuno-oncology agents. The unit operates as part of Johnson & Johnson's Janssen pharmaceutical division and conducts clinical trials to evaluate novel combination therapies for challenging diseases such as metastatic castration-resistant prostate cancer (mCRPC).

Product overview

Johnson & Johnson Innovative Medicine operates as part of the Johnson & Johnson family, developing pharmaceutical treatments. According to available sources, the company is involved in oncology research including bispecific T-cell engager technologies for cancer treatment. The primary product candidate referenced is pasritamig (KLK2-CD3), a first-in-class bispecific antibody being evaluated in clinical trials for metastatic castration-resistant prostate cancer.

Differentiator

Problem solved

Functional benefit

Products and services

• pasritamig (KLK2-CD3) A first-in-class bispecific T-cell engager developed by Johnson & Johnson's Janssen unit, targeting KLK2 and CD3 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is being evaluated in a Phase 1b clinical trial in combination with GI Innovation's immuno-oncology agent GI-102.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• GI InnovationcoreStrategic or Co-development Partner · 19 March 2026Johnson & Johnson (through its Janssen unit) entered into a clinical supply agreement with GI Innovation to evaluate a combination therapy for metastatic castration-resistant prostate cancer (mCRPC) in a Phase 1b clinical trial. The trial combines GI Innovation's immuno-oncology agent GI-102 with Johnson & Johnson's pasritamig (KLK2-CD3), a first-in-class bispecific T-cell engager. The study will be conducted in Korea and the United States, with leading hospitals including Asan Medical Center and Severance Hospital participating alongside Columbia University as the global coordinating site.

Scale indicators1 record

Recent moves3 records

Expansion highlights3 records

Direct peers

• Novartis: Novartis is a global pharma leader with strong oncology and radioligand therapy positions (Pluvicto for mCRPC). Highly comparable as a direct competitor in the mCRPC space targeted by pasritamig.
• AstraZeneca: AstraZeneca is a major oncology player with PARP inhibitors (Lynparza) used in mCRPC, and a robust bispecific/ADC pipeline. Comparable in oncology drug development, mCRPC competition, and large-pharma combination strategies.
• Roche: Roche and its Genentech unit operate one of the world's largest oncology franchises spanning biologics, ADCs, and bispecifics. Directly comparable in oncology R&D scale, bispecific antibody expertise, and global clinical infrastructure.
• Amgen: Amgen is a pioneer in bispecific T-cell engagers with approved assets like Blincyto and Imdelltra. Directly comparable to J&J Innovative Medicine in bispecific antibody technology, oncology pipeline, and biologic manufacturing.
• Bristol Myers Squibb: BMS is a pioneer in immuno-oncology with a deep bispecific T-cell engager portfolio (incl. glofitamab, elranatamab). Directly comparable to J&J Innovative Medicine in oncology focus, bispecific antibody development, and combination therapy strategy.
• Merck & Co. Merck is a top global oncology player led by Keytruda and a deep immuno-oncology pipeline. Comparable to J&J Innovative Medicine as a large-cap pharma with a focus on oncology drug development and combination strategies.
• Pfizer: Pfizer is a global pharmaceutical leader with a major oncology franchise including ADCs and bispecifics (e.g., Padcev, Elrexfio). Directly comparable to J&J Innovative Medicine in scale, oncology focus, and large pharma R&D capabilities.
• Eli Lilly: Lilly has expanded aggressively into oncology with ADCs, bispecifics, and small molecules. Comparable to J&J Innovative Medicine as a large-cap pharma with growing oncology pipeline and combination therapy approach.
• Sanofi: Sanofi is a global pharmaceutical company with growing oncology and immunology franchises. Comparable in scale, branded pharmaceutical focus, and investments in novel biologics including bispecifics.

Broad incumbents

• Gilead Sciences (Kite): Gilead through Kite Pharma is a leading cell therapy company (CAR-T). Comparable to J&J Innovative Medicine in oncology focus and cell therapy investment signaled by their VP, Head of Cell Therapy Discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/jnjinnovativemedicine

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Johnson & Johnson Innovative Medicine